Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer
Jia Wei(North Sichuan Medical University), B Liu(Nanjing Drum Tower Hospital), Xiaoping Qian(Cancer Institute (WIA)), Zhengyun Zou(Nanjing University of Chinese Medicine), Rafael Rosell(Hospital Universitario Dexeus), Ana Giménez‐Capitán(USP Institut Universitari Dexeus), Carlota Costa(USP Institut Universitari Dexeus), Jie Shen(Xinjiang Medical University), Lixia Yu(Comprehensive Blood & Cancer Center), Wenxian Guan(Nanjing University of Chinese Medicine), Xuan Sun(Nanjing Drum Tower Hospital), José Javier Sánchez(Research Institute Hospital 12 de Octubre), Guofeng Yue(Nanjing Drum Tower Hospital)
Cited by 9
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k